Pilot estimation of the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome and multiple chemical sensitivity in the adult population of the Community of Madrid (Spain) using Primary Care-based sampling
e202611096
DOI:
https://doi.org/10.67113/resp.v100i1.1794Keywords:
Multiple Chemical Sensitivity, Cross-Sectional Studies, Prevalence, Primary Health Care, Chronic Fatigue SyndromeAbstract
BACKGROUND // Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Chemical Sensitivity (MCS) are severe multisystem diseases whose clinical recognition has been hindered by social invisibility and diagnostic variability. This has limited the availability of reliable epidemiological data. The aim of this study was to estimate the prevalence of ME/CFS and MCS in the adult population of the Community of Madrid.
METHODS // A cross-sectional descriptive study was conducted among adults over eighteen years belonging to the patient panels of primary care nurses within the Primary Care Services Management. A two‑stage cluster sampling strategy was applied, with a planned sample size of 2,000 participants (550 in the pilot study). Case identification was carried out using the DSQ‑SF, SF‑36, and QEESI questionnaires. The analysis included descriptive statistics (medians, interquartile ranges, and frequencies), chi‑square tests, and mean comparisons using ANOVA and Student’s t‑test.
RESULTS // This paper presents the findings of the pilot study conducted in the Western Primary Care Directorate. Of the 530 individuals who agreed to participate, 280 (52.8%) completed the screening. The estimated prevalence was 2.26% for ME/CFS and 2.64% for MCS. Half of the individuals who met criteria for ME/CFS also met criteria for MCS, resulting in an estimated dual‑condition prevalence of 1.13%.
CONCLUSIONS // The results highlight the epidemiological significance of ME/CFS and MCS. The estimated prevalences are high, clearly exceeding the threshold for rare diseases.
Downloads
References
1. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness [Internet]. Washington, D.C.: National Academies Press; 2015 Mar [consultado 20 jun 2018]. Report. Disponible en: http://www.nap.edu/catalog/19012 doi:10.17226/19012 DOI: https://doi.org/10.17226/19012
2. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management. NICE Guideline NG206 [Internet]. London: NICE; 2021 [consultado 27 mar 2026]. Report. Disponible en: https://www.nice.org.uk/guidance/ng206
3. CONFESQ, DOLFA, SFC-SQM Castilla-La Mancha, ASSESCA. Documento revisión: Guía de actualización en la valoración de fibromialgia, síndrome de fatiga crónica, sensibilidad química múltiples y electrosensibilidad. Encefalomielitis Miálgica/Síndrome de Fatiga Crónica (EM/SFC) [Internet]. 2020 [consultado 27 mar 2026]. Disponible en: https://confesq.org/wp-content/uploads/2020/10/Contradocumento-SFC-EM-VERSIÓN-COMPLETA-1.pdf
4. Valderrama Rodríguez M, Revilla López MC, Blas Diez MP, Vázquez Fernández del Pozo S, Martín Sánchez JI. Actualización de la Evidencia Científica sobre Sensibilidad Química Múltiple (SQM) [Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2015 [consultado 11 abr 2019]. Disponible en: https://www.sanidad.gob.es/fr/biblioPublic/publicaciones.do?metodo=detallePublicacion&publicacion=5153
5. Moya García C, López Rodríguez RM, Peláez Moya S, Lois Cabello M. Documento de consenso. Sensibilidad Química Múltiple [Internet]. Madrid: Ministerio de Sanidad, Política Social e Igualdad; 2011. Report. Disponible en: https://observatoriosaludmujeres.sanidad.gob.es/transversalidadGenero/estudiosInformes/
6. Sabando Carranza JA, Carrasco DC. La enfermedad invisible. FMC. 2013 Aug 1;20(7):383-390. doi: https://doi.org/10.1016/S1134-2072(13)70610-8 DOI: https://doi.org/10.1016/S1134-2072(13)70610-8
7. World Health Organization. International classification of diseases for mortality and morbidity statistics (11th Revision) (ICD-11) [Internet]. 2019 [consultado 28 mar 2026]. Disponible en: https://icd.who.int
8. CONFESQ. Clínicos y pacientes solicitan a la OMS la codificación de la Sensibilidad Química Múltiple-CONFESQ: Coalición Nacional de Fibromialgia, Síndrome de Fatiga Crónica, Electrohipersensibilidad y Sensibilidad Química Múltiple. [Internet]. 2023 [consultado 28 mar 2026]. Disponible en: https://confesq.org/?p=29232
9. Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020 Feb 24;18(1). doi: https://doi.org/10.1186/s12967-020-02269-0. PubMed PMID: 32093722. DOI: https://doi.org/10.1186/s12967-020-02269-0
10. Estévez-López F, Mudie K, Wang-Steverding X, Bakken IJ, Ivanovs A, Castro-Marrero J et al. Systematic review of the epidemiological burden of myalgic encephalomyelitis/chronic fatigue syndrome across europe: Current evidence and euromene research recommendations for epidemiology. J Clin Med. 2020;9(5). doi: https://doi.org/10.3390/jcm9051557 DOI: https://doi.org/10.3390/jcm9051557
11. Azuma K, Uchiyama I, Katoh T, Ogata H, Arashidani K, Kunugita N. Prevalence and Characteristics of Chemical Intolerance: A Japanese Population-Based Study. Arch Environ Occup Health. 2015;70(6):341-353. doi: https://doi.org/10.1080/19338244.2014.926855. PubMed PMID: 25137616. DOI: https://doi.org/10.1080/19338244.2014.926855
12. Karvala K, Sainio M, Palmquist E, Nyback MH, Nordin S. Prevalence of various environmental intolerances in a Swedish and Finnish general population. Environ Res. 2018 Feb;161:220-228. doi: https://doi.org/10.1016/j.envres.2017.11.014. PubMed PMID: 29161654. DOI: https://doi.org/10.1016/j.envres.2017.11.014
13. Pigatto PD, Guzzi G. Prevalence and risk factors for multiple chemical sensitivity in Australia. Prev Med Rep. 2019 Jun;14:100856. doi: https://doi.org/10.1016/j.pmedr.2019.100856. PubMed PMID: 31193443. DOI: https://doi.org/10.1016/j.pmedr.2019.100856
14. Steinemann A. National Prevalence and Effects of Multiple Chemical Sensitivities. J Occup Environ Med. 2018 Mar;60(3):e152-156. doi: https://doi.org/10.1097/JOM.0000000000001272. PubMed PMID: 29329146. DOI: https://doi.org/10.1097/JOM.0000000000001272
15. Zucco GM, Doty RL. Multiple Chemical Sensitivity. Brain Sci. 2021 Dec;12(1). doi: https://doi.org/10.3390/brainsci12010046. PubMed PMID: 35053790. DOI: https://doi.org/10.3390/brainsci12010046
16. Palmer RF, Jaén CR, Perales RB, Rincon R, Forster JN, Miller CS. Three questions for identifying chemically intolerant individuals in clinical and epidemiological populations: The Brief Environmental Exposure and Sensitivity Inventory (BREESI). PLoS One. 2020 Sep 1;15(9). doi: https://doi.org/10.1371/JOURNAL.PONE.0238296. PubMed PMID: 32936802. DOI: https://doi.org/10.1371/journal.pone.0238296
17. Alameda Cuesta A. Malestares en el margen: sujetos y tránsitos en la fibromialgia, el síndrome de fatiga crónica y la sensibilidad química múltiple. Barcelona: Edicions Bellaterra; 2018.
18. Collado A, Gomez E, Coscolla R, Sunyol R, Solé E, Rivera J et al. Work, family and social environment in patients with Fibromyalgia in Spain: an epidemiological study: EPIFFAC study. BMC Health Serv Res. 2014;14(1). doi: https://doi.org/10.1186/S12913-014-0513-5. PubMed PMID: 25385047. DOI: https://doi.org/10.1186/s12913-014-0513-5
19. Palmer RF, Walker T, Kattari D, Rincon R, Perales RB, Jaén CR et al. Validation of a Brief Screening Instrument for Chemical Intolerance in a Large U.S. National Sample. Int J Environ Res Public Health. 2021 Aug;18(16). doi: https://doi.org/10.3390/ijerph18168714. PubMed PMID: 34444461. DOI: https://doi.org/10.3390/ijerph18168714
20. Jason L. DePaul Symptom Questionnaire-Short Form (DSQ-SF) SPSS Scoring Syntax [Internet]. 2019. Report. Disponible en: https://www.researchgate.net/publication/358307098_DePaul_Symptom_Questionnaire_-_Short_Form_DSQ-SF_SPSS_Scoring_Syntax
21. Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM et al. El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit [Internet]. 2005 [consultado 28 mar 2023];19(2):135-150. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0213-91112005000200007&lng=es&nrm=iso&tlng=es DOI: https://doi.org/10.1157/13074369
22. Mena G, Sequera VG, Nogué-Xarau S, Ríos J, Bertran MJ, Trilla A. Traducción y adaptación transcultural del cuestionario Quick Environmental Exposure and Sensitivity Inventory a la población española. Med Clin (Barc). 2013 Apr 15;140(7):302-304. doi: https://doi.org/10.1016/J.MEDCLI.2012.10.024. PubMed PMID: 23347502. DOI: https://doi.org/10.1016/j.medcli.2012.10.024
23. Carreño À, Estrada MD, Vivanco-Hidalgo RM. Epidemiologia de les síndromes de sensibilització central a Catalunya. Fibromiàlgia, síndrome de fatiga crònica i síndrome de sensibilitat química múltiple [Internet]. 2023 [consultado 28 mar 2026]. Report. Disponible en: https://hdl.handle.net/11351/10503
24. Dehlia A, Guthridge MA. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. Journal of Infection. 2024 Dec 1;89(6):106297. doi: https://doi.org/10.1016/j.jinf.2024.106297. PubMed PMID: 39353473. DOI: https://doi.org/10.1016/j.jinf.2024.106297
25. Hadidchi R, Patel B, Madan J, Liu A, Henry S, Duong TQ. Elevated risk of new-onset chronic fatigue syndrome/myalgic encephalomyelitis up to four years after SARS-CoV-2 infection. J Transl Med. 2025 Dec 1;23(1). doi: https://doi.org/10.1186/s12967-025-06625-w. PubMed PMID: 40702518. DOI: https://doi.org/10.1186/s12967-025-06625-w
26. Unger ER, Lin JMS, Wisk LE, Yu H, L’Hommedieu M, Lavretsky H et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.JAMA Netw Open. 2024 Jul 1;7(7):e2423555-e2423555. doi: https://doi.org/10.1001/jamanetworkopen.2024.23555. PubMed PMID: 39046739. DOI: https://doi.org/10.1001/jamanetworkopen.2024.23555
27. Apostolou E, Rosén A. Epigenetic reprograming in myalgic encephalomyelitis/chronic fatigue syndrome: A narrative of latent viruses. J Intern Med. 2024 Jul 1;296(1):93-115. doi: https://doi.org/10.1111/joim.13792. PubMed PMID: 38693641. DOI: https://doi.org/10.1111/joim.13792
28. Robins S, Molot J, Peris R. Prevalence of Multiple Chemical Sensitivity in Canada Between 2000 and 2020. Int J Environ Res Public Health. 2026 Feb 1;23(2). doi: https://doi.org/10.3390/ijerph23020236 DOI: https://doi.org/10.3390/ijerph23020236
29. Genovese G, Rizzo CE, Mistretta A, Leonforte F, Squeri R, Signorelli C et al. Multiple Chemical Sensitivity: an Italian prevalence multicentric survey. Front Public Health. 2025;13. doi: https://doi.org/10.3389/fpubh.2025.1685040. PubMed PMID: 41426713. DOI: https://doi.org/10.3389/fpubh.2025.1685040
30. Lu X, Hojo S, Mizukoshi A, Katoh T. Prevalence and correlation of multiple chemical sensitivity and electromagnetic hypersensitivity with age, sex, and depression in the Japanese population: a retrospective study. BMC Public Health. 2023 Dec 1;23(1). doi: https://doi.org/10.1186/s12889-023-16152-2. PubMed PMID: 37344806. DOI: https://doi.org/10.1186/s12889-023-16152-2
31. Hojo S, Mizukoshi A, Azuma K, Okumura J, Mizuki M, Miyata M. New criteria for multiple chemical sensitivity based on the quick environmental exposure and sensitivity inventory developed in response to rapid changes in ongoing chemical exposures among Japanese. PLoS One. 2019 Apr 1;14(4). doi: https://doi.org/10.1371/journal.pone.0215144. PubMed PMID: 31026284. DOI: https://doi.org/10.1371/journal.pone.0215144
32. Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health. 1999;15(3–4):370-385. doi: https://doi.org/10.1177/074823379901500311. PubMed PMID: 10416289. DOI: https://doi.org/10.1177/074823379901500311
33. Castro-Marrero J, Faro M, Aliste L, Sáez-Francàs N, Calvo N, Martínez-Martínez A et al. Comorbidity in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Nationwide Population-Based Cohort Study. Psychosomatics. 2017 Sep;58(5):533-543. doi: https://doi.org/10.1016/j.psym.2017.04.010. PubMed PMID: 28596045. DOI: https://doi.org/10.1016/j.psym.2017.04.010
34. Oter-Quintana C, Alameda-Cuesta A, Brito-Brito PR, Parro-Moreno AI, Alcolea-Cosín MT, González-Gil T et al. Psychosocial Nursing Diagnoses of Individuals With Myalgic Encephalomyelitis-Chronic Fatigue Syndrome: A Descriptive Study. Nurs Open. 2025 May;12(5):e70212. doi: https://doi.org/10.1002/nop2.70212. PubMed PMID: 40304221. DOI: https://doi.org/10.1002/nop2.70212
35. McManimen SL, McClellan D, Stoothoff J, Jason LA. Effects of unsupportive social interactions, stigma, and symptoms on patients with myalgic encephalomyelitis and chronic fatigue syndrome. J Community Psychol. 2018 Nov 1;46(8):959-971. doi: https://doi.org/10.1002/jcop.21984. PubMed PMID: 30311972. DOI: https://doi.org/10.1002/jcop.21984
36. Froehlich L, Hattesohl DBR, Cotler J, Jason LA, Scheibenbogen C, Behrends U. Causal attributions and perceived stigma for myalgic encephalomyelitis/chronic fatigue syndrome. J Health Psychol. 2022 Sep 1;27(10):2291-2304. doi: https://doi.org/10.1177/13591053211027631. PubMed PMID: 34240650. DOI: https://doi.org/10.1177/13591053211027631
37. Nezamdoust B, Ruel E. Contested and neglected: Social and medical marginalization in severe Chronic Fatigue Syndrome. Soc Sci Med. 2026 Jan 1;388. doi: https://doi.org/10.1016/j.socscimed.2025.118766. PubMed PMID: 41223774. DOI: https://doi.org/10.1016/j.socscimed.2025.118766
38. Yousufzai SJ, Psaradellis E, Peris R, Barakat C. A Qualitative Exploration of Policy, Institutional, and Social Misconceptions Faced by Individuals with Multiple Chemical Sensitivity. Int J Environ Res Public Health. 2025 Sep 1;22(9). doi: https://doi.org/10.3390/ijerph22091383. PubMed PMID: 41007527. DOI: https://doi.org/10.3390/ijerph22091383
39. Driesen L, Patton R, John M. The impact of multiple chemical sensitivity on people’s social and occupational functioning; a systematic review of qualitative research studies. Journal of Psychosomatic Research. Elsevier Inc.; 2020. doi: https://doi.org/10.1016/j.jpsychores.2020.109964. PubMed PMID: 32114179. DOI: https://doi.org/10.1016/j.jpsychores.2020.109964
40. Clark I. When Avoiding Chemicals Means Avoiding Others: Relational Exposures and Multiple Chemical Sensitivity. Soc Sci. 2024 Oct 1;13(10). doi: https://doi.org/10.3390/socsci13100528 DOI: https://doi.org/10.3390/socsci13100528
Downloads
Additional Files
- TABLA 1 (Español (España))
- TABLA 2 (Español (España))
- TABLA 3 (Español (España))
- TABLA 4 (Español (España))
- ANEXO I (Español (España))
- ANEXO II (Español (España))
- ANEXO III (Español (España))
- ANEXO IV (Español (España))
- ANEXO V (Español (España))
- ANEXO VI (a) (Español (España))
- ANEXO VI (b) (Español (España))
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Almudena Alameda Cuesta, María Gema Cid Expósito, Cristina Nieto Muñoz, Ana Talavera Sáez, Ángel Lizcano Álvarez, Saray Blanco Abril, Cristina Oter Quintana, Jesús Esteban Hernández

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.







![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
